Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Tags:
BioPharmaceutical Medical Device Business Strategies

OrbiMed Closes $550 Million Fund

This article was originally published in Start Up

  • Analysis

Executive Summary

OrbiMed Advisers just closed a $550 million fund, a tick more than its previous general fund and raised mostly from previous backers. OrbiMed’s general partners say they’ll make no radical departures from their previous formula despite the upheaval brought on by the recession and the federal health care reform saga.
Table

View full table

Advertisement

Related Content

Pink Sheet
Sidestepping the "Washout," SV Life Sciences Closes $523 Million Fund
Pink Sheet
Sidestepping the "Washout," SV Life Sciences Closes $523 Million Fund
Scrip
Biotech Backers Are Learning to Live with Exit-by-Earn-out
Scrip
Biotech Backers Are Learning to Live with Exit-by-Earn-out
Scrip
2009's Private Biotech Acquisitions Are a Tale of Two Step-Ups
In Vivo
Biopharma Trends: Nowhere To Go But Up
In Vivo
Biopharma Trends: Nowhere To Go But Up
Scrip
2009's Private Biotech Acquisitions Are a Tale of Two Step-Ups
In Vivo
Tighter FDA Review Squeezing Device VCs
In Vivo
Tighter FDA Review Squeezing Device VCs

Topics

Related Companies

Related Deals

Advertisement
Tags:
BioPharmaceutical Medical Device Business Strategies
UsernamePublicRestriction

Register

SC091943

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By